Observational studyJournal of pediatric gastroenterology and nutrition2026
Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease.
Observational study in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesInfliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This study evaluated the safety and efficacy of switching from originator IFX to IFX biosimilar CT-P13 in IBD.
methodsIn this single-center observational study, we investigated all pediatric patients with IBD on maintenance IFX therapy who were switched from originator (Remicade®) to CT-P13 (Inflectra®, switch A in cohort A) in 2018 and to CT-P13 (Remsima®, switch B in cohort B) in 2022. Cohort C includes patients who underwent both switches. Demographics, disease activity, remission rates and IFX trough levels were collected from 6 months before to 6 months after each switch.
resultsA total of 42 children (cohort A) and 44 children (cohort B) had a single switch to CT-P13; 14 (cohort C) had multiple switches. Median IFX trough concentration was 5.7 ([3.8-9.3) and 9.0 (6.2-11.7) µg/mL versus 6.5 (3.9-8.6) and 9.22 (7.9-10.5) µg/mL 6 months after switch in cohort A and B and 4.3 (3.4-10.9) versus 7.9 (6.9-9.7) and 9.3 (8.3-10.3) versus 9.4 (7.9-10.6) for respectively both switches in cohort C (all p > 0.05). Antibodies to IFX developed in one patient post-switch. Clinical/biological remission rates remained stable. No clinically significant changes in inflammatory biomarkers and safety profile were noted before and after switch.
conclusionsSwitching to CT-P13 biosimilars appears to maintain remission without relevant changes in pharmacokinetics, disease activity, or adverse events in pediatric patients with IBD. Further studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.